Acoramidis,
does it really help with Improved composite outcome of mortality, cardiovascular hospitalization, and functional decline in ATTR-CM?
research showsAcoramidis met the 30-month four-level ATTRibute-CM hierarchy. Among 632 randomized patients, the modified intention-to-treat analysis of 611 gave a win ratio of 1.8 (95% CI 1.4 to 2.2). The order was all-cause death, cumulative cardiovascular hospitalization, change in NT-proBNP, and six-minute walk distance, yielding B with 68 points.
ads claimSaying simply that survival was proven conceals the hierarchical composite. The accurate claim is improvement in an ordered comparison of death, hospitalization, a laboratory marker, and walking function.
Useful facts when choosing a product
- Acoramidis is an oral prescription TTR tetramer stabilizer; it treats the same ATTR-CM disease as vutrisiran through a different mechanism.
- United States labeling directs 712 mg orally twice daily with tablets swallowed whole.
- Gastrointestinal adverse events such as diarrhea and upper abdominal pain were more frequent in the trial.
- Replacement of or combination with other ATTR-CM drugs requires specialist cardiac amyloidosis care.
Chamgap Semantic Classification Code
Candidate index · review held
M.acoramidis.oral.composite-outcome-of-mortality-cardiovascular-hospitalization-and-functional-decline-in-attr-cm.improve.placeboMedicinal interventions > Acoramidis > Oral > composite outcome of mortality, cardiovascular hospitalization, and functional decline in ATTR-CM > Improvement claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
ATTRibute-CM randomized 632 patients and analyzed 611 in the modified intention-to-treat primary analysis. At 30 months, the hierarchy succeeded with win ratio 1.8 (95% CI 1.4 to 2.2): all-cause death, cumulative cardiovascular hospitalization, change in NT-proBNP, then six-minute walk distance. It mixes hard, surrogate, and functional outcomes and is not mortality benefit alone.
Why this is classified as B (68)
A mixed hierarchy rather than standalone mortality benefit is less direct than verdict 1621, which is B with 78 points, so this verdict is B with 68 points.
Counterpoint. The composite direction is persuasive, but no head-to-head trial establishes superiority over vutrisiran or tafamidis.
Rejudgment record. Cross-check applied — One large manufacturer-funded trial met a hierarchical primary endpoint mixing hard, surrogate, and functional outcomes
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved hierarchical composite of death, cardiovascular hospitalization, laboratory, and functional outcomes | B | The primary endpoint succeeded with a win ratio of 1.8. |
| Reduced all-cause mortality alone | ? | Success of the hierarchy does not independently establish mortality benefit alone. |
| Improved NT-proBNP | C | This is a surrogate marker for clinical benefit. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Gillmore JD et al.; ATTRibute-CM Investigators. 2024 | Peer-reviewed original phase 3 double-blind randomized placebo-controlled trial | 632 randomized; 611 in the primary analysis | Eidos Therapeutics | Primary: hierarchy of death, cardiovascular hospitalization, NT-proBNP, and six-minute walk distance | Primary endpoint met; win ratio 1.8 (95% CI 1.4 to 2.2), p<0.001. | Pivotal confirmatory randomized trial |
| U.S. FDA ATTRUBY multidisciplinary review. 2024 | Regulatory clinical review | 632 in the pivotal efficacy trial | Regulatory document | Hierarchical composite and safety | Confirmed primary endpoint success, analysis population, and composite structure. | Regulatory cross-check |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Final verification and publication gate: Codex · Evidence date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Acoramidis x improved hierarchical composite outcome in ATTR-CM — Evidence Grade B·68. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/acoramidis-attr-cm-hierarchical-composite-outcome/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.